2024
Use of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks
Lu Y, Keeley E, Barrette E, Cooper-DeHoff R, Dhruva S, Gaffney J, Gamble G, Handke B, Huang C, Krumholz H, McDonough C, Schulz W, Shaw K, Smith M, Woodard J, Young P, Ervin K, Ross J. Use of electronic health records to characterize patients with uncontrolled hypertension in two large health system networks. BMC Cardiovascular Disorders 2024, 24: 497. PMID: 39289597, PMCID: PMC11409735, DOI: 10.1186/s12872-024-04161-x.Peer-Reviewed Original ResearchConceptsElectronic health recordsHealth recordsHealth systemUncontrolled hypertensionUse of electronic health recordsHypertension managementElectronic health record systemsOneFlorida Clinical Research ConsortiumElectronic health record dataYale New Haven Health SystemBP measurementsICD-10-CM codesHealth system networkPublic health priorityICD-10-CMIncidence rate of deathElevated BP measurementsElevated blood pressure measurementsHealthcare visitsAmbulatory careHealth priorityRetrospective cohort studyEHR dataOneFloridaBlood pressure measurementsComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM
Khera R, Aminorroaya A, Dhingra L, Thangaraj P, Pedroso Camargos A, Bu F, Ding X, Nishimura A, Anand T, Arshad F, Blacketer C, Chai Y, Chattopadhyay S, Cook M, Dorr D, Duarte-Salles T, DuVall S, Falconer T, French T, Hanchrow E, Kaur G, Lau W, Li J, Li K, Liu Y, Lu Y, Man K, Matheny M, Mathioudakis N, McLeggon J, McLemore M, Minty E, Morales D, Nagy P, Ostropolets A, Pistillo A, Phan T, Pratt N, Reyes C, Richter L, Ross J, Ruan E, Seager S, Simon K, Viernes B, Yang J, Yin C, You S, Zhou J, Ryan P, Schuemie M, Krumholz H, Hripcsak G, Suchard M. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes A Multinational, Federated Analysis of LEGEND-T2DM. Journal Of The American College Of Cardiology 2024, 84: 904-917. PMID: 39197980, DOI: 10.1016/j.jacc.2024.05.069.Peer-Reviewed Original ResearchConceptsGLP-1 RAsSecond-line agentsGLP-1Antihyperglycemic agentsCardiovascular diseaseMACE riskGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsEffects of SGLT2isType 2 diabetes mellitusPeptidase-4 inhibitorsAdverse cardiovascular eventsCox proportional hazards modelsRandom-effects meta-analysisCardiovascular risk reductionTarget trial emulationProportional hazards modelIntravascular Microaxial Left Ventricular Assist Device Manufacturer Payments to Cardiologists and Use of Devices
Dhruva S, Ross J, Steinman M, Gan S, Muluk S, Anderson T. Intravascular Microaxial Left Ventricular Assist Device Manufacturer Payments to Cardiologists and Use of Devices. JAMA 2024, 331: 1499-1501. PMID: 38598231, PMCID: PMC11007652, DOI: 10.1001/jama.2024.4682.Peer-Reviewed Original Research
2022
Safety and Effectiveness of a Catheter With Contact Force and 6-Hole Irrigation for Ablation of Persistent Atrial Fibrillation in Routine Clinical Practice
Dhruva SS, Zhang S, Chen J, Noseworthy PA, Doshi AA, Agboola KM, Herrin J, Jiang G, Yu Y, Cafri G, Farr K, Ervin KR, Ross JS, Coplan PM, Drozda JP. Safety and Effectiveness of a Catheter With Contact Force and 6-Hole Irrigation for Ablation of Persistent Atrial Fibrillation in Routine Clinical Practice. JAMA Network Open 2022, 5: e2227134. PMID: 35976649, PMCID: PMC9386540, DOI: 10.1001/jamanetworkopen.2022.27134.Peer-Reviewed Original ResearchConceptsPersistent AF ablationRoutine clinical practiceMercy HealthAF ablationMayo ClinicSafety outcomesClinical practiceCatheter groupCohort studyCatheter ablationPersistent AFParoxysmal atrial fibrillation ablationThermocool SmartTouch catheterComposite of deathPrimary safety outcomeAtrial fibrillation ablationPersistent atrial fibrillationElectronic health record dataHealth system dataHealth record dataHealth care systemSmartTouch catheterThromboembolic eventsFibrillation ablationProcedural complicationsAssociation Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults
Brito JP, Deng Y, Ross JS, Choi NH, Graham DJ, Qiang Y, Rantou E, Wang Z, Zhao L, Shah ND, Lipska KJ. Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults. JAMA Internal Medicine 2022, 182: 418-425. PMID: 35226058, PMCID: PMC8886450, DOI: 10.1001/jamainternmed.2022.0045.Peer-Reviewed Original ResearchConceptsComparative effectiveness research studyIndex dateProportion of patientsTSH levelsNormal TSH levelsMIU/LThyrotropin levelsLevothyroxine productsGeneric levothyroxineNational administrative claims databasePropensity-matched patient pairsBaseline TSH levelsMean TSH levelsThyroid replacement therapyAdministrative claims databaseCurrent guideline recommendationsSerum thyrotropin levelsOptumLabs Data WarehouseStandardized mean differenceLevothyroxine doseLevothyroxine prescriptionsPropensity matchingGuideline recommendationsClaims databaseReplacement therapyRates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults
Brito JP, Deng Y, Ross JS, Choi NH, Graham DJ, Qiang Y, Rantou E, Wang Z, Zhao L, Shah ND, Lipska KJ. Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults. Endocrine 2022, 76: 349-358. PMID: 35107758, PMCID: PMC9210352, DOI: 10.1007/s12020-022-02987-z.Peer-Reviewed Original ResearchConceptsL-thyroxineLarge administrative claims databaseMultivariate logistic regression analysisAdministrative claims databaseThyroid hormone valuesLogistic regression analysisNumber of pharmaciesSettingRetrospective studyPrescription fillsTreatment initiationGuideline recommendationsThyroid surgeryClaims databaseFill dateMean ageHormone valuesLevothyroxine preparationsMore pharmaciesPractice guidelinesAdditional studiesGeneric preparationsNational dataAmerican adultsPatientsRegression analysisAssociation of Psychiatric Diagnoses and Medicaid Coverage with Length of Stay Among Inpatients Discharged to Skilled Nursing Facilities
Bartlett VL, Ross JS, Balasuriya L, Rhee TG. Association of Psychiatric Diagnoses and Medicaid Coverage with Length of Stay Among Inpatients Discharged to Skilled Nursing Facilities. Journal Of General Internal Medicine 2022, 37: 3070-3079. PMID: 35048298, PMCID: PMC9485316, DOI: 10.1007/s11606-021-07320-4.Peer-Reviewed Original ResearchConceptsSkilled nursing facilitiesLength of staySubstance use diagnosesPsychiatric diagnosisHospital stayDischarge diagnosisPrimary payorUse diagnosesNursing facilitiesMedicaid coverageRetrospective cross-sectional study designPrimary discharge diagnosisCross-sectional study designNational Inpatient SampleDiagnosis-related groupsMultivariable adjustmentGeometric mean lengthMedian lengthInpatient hospitalizationInpatient SampleMedicaid patientsMedicare patientsInpatient dischargesMAIN OUTCOMEPatients
2021
Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration
Sankar A, Swanson KM, Zhou J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration. JAMA Network Open 2021, 4: e2136662. PMID: 34851398, PMCID: PMC8637256, DOI: 10.1001/jamanetworkopen.2021.36662.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmbulatory CareAnti-Bacterial AgentsBronchitisCross-Sectional StudiesDrug LabelingDrug PrescriptionsFemaleFluoroquinolonesHealth Plan ImplementationHumansInterrupted Time Series AnalysisMaleMedicareMiddle AgedPractice Patterns, Physicians'SinusitisUnited StatesUnited States Food and Drug AdministrationUrinary Tract InfectionsConceptsPrescribing of fluoroquinolonesCross-sectional studyBlack box warningFDA warningCare physiciansPrescribing levelsBox warningMAIN OUTCOMEUS FoodDrug AdministrationMedicare administrative claims dataUncomplicated urinary tract infectionsNon-primary care physiciansAcute care visitsUrinary tract infectionFDA black box warningPrimary care physiciansAdministrative claims dataCase mix indexFluoroquinolone prescriptionsPrescribing trendsCare visitsPrescribing ratesTract infectionsOutpatient visitsUnplanned hospital visits after ambulatory surgical care
Bongiovanni T, Parzynski C, Ranasinghe I, Steinman MA, Ross JS. Unplanned hospital visits after ambulatory surgical care. PLOS ONE 2021, 16: e0254039. PMID: 34283840, PMCID: PMC8291649, DOI: 10.1371/journal.pone.0254039.Peer-Reviewed Original ResearchConceptsUnplanned hospital visitsSame-day surgeryHospital visitsAmbulatory surgeryHealthcare costsDischarge care qualityHospital visit ratesNumber of comorbiditiesEmergency department visitsMajority of surgeriesAmbulatory surgical careSpecific patient populationsQuality's Healthcare CostMedicaid Services measuresPatient hospital visitsQuality of careType of procedureDepartment visitsHospital admissionPatient characteristicsOutpatient settingPatient populationProcedure typeSurgical careSurgical facilitiesMedicare beneficiaries' plans for the COVID‐19 vaccine in Fall 2020, and why some planned to decline
Holaday LW, Balasuriya L, Roy B, Ross JS, Oladele CR. Medicare beneficiaries' plans for the COVID‐19 vaccine in Fall 2020, and why some planned to decline. Journal Of The American Geriatrics Society 2021, 69: 2434-2437. PMID: 33990945, PMCID: PMC8242621, DOI: 10.1111/jgs.17285.Peer-Reviewed Original ResearchReporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.Peer-Reviewed Original ResearchConceptsNovel cancer therapeuticsPostmarketing studyBlack patientsCancer therapeuticsDemographic dataOlder adultsUS cancer populationUS Cancer StatisticsCross-sectional studyRace/ethnicityParticipants' demographic characteristicsPercentage of trialsPatient sexCancer populationClinical studiesCancer statisticsMAIN OUTCOMEDrug AdministrationFDA approvalStudy participantsCancer typesDemographic characteristicsDemographic informationStudy samplePatientsAge‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018
Rhee TG, Kumar M, Ross JS, Coll PP. Age‐Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011–2018. Journal Of The American Geriatrics Society 2021, 69: 1272-1282. PMID: 33598936, PMCID: PMC9869399, DOI: 10.1111/jgs.17038.Peer-Reviewed Original ResearchConceptsUse of aspirinStatin useAspirin useCardiovascular riskSecondary preventionMedication usePrimary preventionAge-related trajectoriesAge 50Prevention treatmentAngina/angina pectorisLow-dose aspirin dailyLong-term statin useOlder adultsDaily aspirin usePrimary prevention treatmentSecondary prevention treatmentSubsequent CVD eventsFirst cardiovascular eventCoronary heart diseaseAdults Aged 50Nutrition Examination SurveyCross-sectional studyHealth Interview SurveyNon-institutionalized adultsPhysician variation in the de‐adoption of ineffective statin and fibrate therapy
Everhart A, Desai NR, Dowd B, Herrin J, Higuera L, Jeffery MM, Jena AB, Ross JS, Shah ND, Smith LB, Karaca‐Mandic P. Physician variation in the de‐adoption of ineffective statin and fibrate therapy. Health Services Research 2021, 56: 919-931. PMID: 33569804, PMCID: PMC8522575, DOI: 10.1111/1475-6773.13630.Peer-Reviewed Original ResearchMeSH KeywordsAgedDiabetes Mellitus, Type 2Drug Therapy, CombinationDrug UtilizationFemaleFibric AcidsGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsHypolipidemic AgentsLongitudinal StudiesMaleMedicare Part CMiddle AgedPractice Guidelines as TopicPractice Patterns, Physicians'Risk FactorsUnited StatesConceptsMedicare Advantage patientsType 2 diabetic patientsACCORD lipid trialFibrate useAdvantage patientsCommercial patientsPhysician characteristicsLIPID trialFibrate therapyDiabetic patientsPhysician variationDiabetes careType 2 diabetes diagnosisContinuous insurance enrollmentPatient diabetes carePhysician random effectsGlucose-lowering drugsElectronic health record dataHealth record dataReal-world data assetConcurrent statinCardiovascular eventsStatin usersClinical evidenceManagement visitsUse of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz AP, Masoudi FA, Messenger JC, Parzynski CS, Ngufor CG, Girotra S, Amin AP, Shah ND, Desai NR. Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Network Open 2021, 4: e2037748. PMID: 33616664, PMCID: PMC7900859, DOI: 10.1001/jamanetworkopen.2020.37748.Peer-Reviewed Original ResearchMeSH KeywordsAgedAssisted CirculationCross-Sectional StudiesExtracorporeal Membrane OxygenationFemaleHeart ArrestHeart-Assist DevicesHospitals, High-VolumeHospitals, Low-VolumeHospitals, TeachingHumansIntra-Aortic Balloon PumpingMaleMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionRisk FactorsShock, CardiogenicConceptsMicroaxial left ventricular assist deviceIntra-aortic balloon pumpLeft ventricular assist devicePercutaneous coronary interventionAcute myocardial infarctionMechanical circulatory support devicesCardiogenic shockHospital-level variationSignificant hospital-level variationCirculatory support devicesMCS devicesUse of IABPDevice useMedian proportionAcute Myocardial Infarction ComplicatedCardiology-National Cardiovascular Data RegistryChest Pain-MI RegistryLimited clinical trial evidenceNational Cardiovascular Data RegistryMyocardial Infarction ComplicatedFirst medical contactSupport devicesClinical trial evidenceExtracorporeal membrane oxygenationCoronary artery stenosisComparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019
McCoy RG, Van Houten HK, Deng Y, Mandic PK, Ross JS, Montori VM, Shah ND. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Network Open 2021, 4: e2035792. PMID: 33523188, PMCID: PMC7851726, DOI: 10.1001/jamanetworkopen.2020.35792.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsDipeptidyl peptidase-4 inhibitorsCommercial insurance beneficiariesMedicare Advantage beneficiariesDPP-4i treatmentGLP-1RAsType 2 diabetesInsurance beneficiariesMedicare AdvantageGlucose levelsGlucagonlike Peptide-1 Receptor AgonistsPeptide-1 receptor agonistsHealth plansCommercial health insurance plansGLP-1RA treatmentRetrospective cohort studyCotransporter 2 inhibitorsInitiation of treatmentPeptidase-4 inhibitorsLow-income patientsSeparate logistic regression modelsAdministrative claims dataCommercial health plansAdjusted annual rateLogistic regression models
2020
Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation
Yao X, Inselman JW, Ross JS, Izem R, Graham DJ, Martin DB, Thompson AM, Ross Southworth M, Siontis KC, Ngufor CG, Nath KA, Desai NR, Nallamothu BK, Saran R, Shah ND, Noseworthy PA. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circulation Cardiovascular Quality And Outcomes 2020, 13: e006515. PMID: 33012172, PMCID: PMC7580213, DOI: 10.1161/circoutcomes.120.006515.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnticoagulantsAntithrombinsAtrial FibrillationComparative Effectiveness ResearchDabigatranDatabases, FactualFactor Xa InhibitorsFemaleGlomerular Filtration RateHemorrhageHumansKidneyMaleMiddle AgedPyrazolesPyridonesRenal Insufficiency, ChronicRetrospective StudiesRisk AssessmentRisk FactorsRivaroxabanTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsGlomerular filtration rateKidney functionMajor bleedingAtrial fibrillationOral anticoagulantsLower riskFiltration rateComparative effectivenessGlomerular filtration rate categoriesUS administrative claims databaseFalsification end pointsKidney function declineReduced kidney functionProportion of patientsAdministrative claims databaseSubstantial residual confoundingBaseline characteristicsFunction declineClaims databaseComparative safetyResidual confoundingTreatment weightingSimilar riskTreatment groupsPatientsComparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels
Brito JP, Ross JS, Sangaralingham L, Dutcher SK, Graham DJ, Wang Z, Wu Y, Yao X, Smallridge RC, Bernet V, Shah ND, Lipska KJ. Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels. JAMA Network Open 2020, 3: e2017645. PMID: 32997127, PMCID: PMC7527873, DOI: 10.1001/jamanetworkopen.2020.17645.Peer-Reviewed Original ResearchConceptsNormal thyrotropin levelsPropensity score-matched patientsThyrotropin levelsLevothyroxine prescriptionsThyrotropin valuesProportion of patientsAdministrative claims databaseMonths of initiationMIU/LMild thyroid dysfunctionLongitudinal cohort studyMedicare Advantage enrolleesNormal thyrotropin valuesEligible patientsInitial therapyLevothyroxine formulationsCohort studyThyroid dysfunctionClaims databaseGeneric levothyroxineLevothyroxineMAIN OUTCOMENormal rangePatientsNormal vsAssociation of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Dhruva SS, Ross JS, Mortazavi BJ, Hurley NC, Krumholz HM, Curtis JP, Berkowitz A, Masoudi FA, Messenger JC, Parzynski CS, Ngufor C, Girotra S, Amin AP, Shah ND, Desai NR. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA 2020, 323: 734-745. PMID: 32040163, PMCID: PMC7042879, DOI: 10.1001/jama.2020.0254.Peer-Reviewed Original ResearchMeSH KeywordsAgedCause of DeathExtracorporeal Membrane OxygenationFemaleHeart ArrestHeart-Assist DevicesHemorrhageHospital MortalityHumansIntra-Aortic Balloon PumpingMaleMatched-Pair AnalysisMiddle AgedMyocardial InfarctionPercutaneous Coronary InterventionPropensity ScoreRegistriesRetrospective StudiesShock, CardiogenicST Elevation Myocardial InfarctionConceptsMicroaxial left ventricular assist deviceIntra-aortic balloon pumpLeft ventricular assist deviceAcute myocardial infarctionPercutaneous coronary interventionNational Cardiovascular Data RegistryCardiogenic shockHemodynamic supportMyocardial infarctionRegistry-based retrospective cohort studyCardiology-National Cardiovascular Data RegistryChest Pain-MI RegistryST-elevation myocardial infarctionMechanical circulatory support devicesGreater hemodynamic supportHospital major bleedingRetrospective cohort studyPropensity-matched pairsCirculatory support devicesVentricular assist deviceClinical laboratory dataHospital mortalityMajor bleedingHospital deathCohort study
2019
Accidental drug overdose deaths in Connecticut, 2012–2018: The rise of polysubstance detection?
Rhee TG, Ross JS, Rosenheck RA, Grau LE, Fiellin DA, Becker WC. Accidental drug overdose deaths in Connecticut, 2012–2018: The rise of polysubstance detection? Drug And Alcohol Dependence 2019, 205: 107671. PMID: 31706248, DOI: 10.1016/j.drugalcdep.2019.107671.Peer-Reviewed Original ResearchConceptsOverdose deathsNumber of deathsPolysubstance useDrug-related overdose deathsOpioid-involved overdose deathsFentanyl-related deathsNon-Hispanic whitesChief Medical ExaminerAccidental overdose deathsOverall deathOverdose incidentsStratified analysisConnecticut OfficeAccidental drugConnecticut residentsFentanylDeathUse statusMedical examinersSeparate analysisResidentsStatistical analysisAdoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study
McCoy R, Dykhoff HJ, Sangaralingham L, Ross JS, Karaca-Mandic P, Montori VM, Shah N. Adoption of New Glucose-Lowering Medications in the U.S.—The Case of SGLT2 Inhibitors: Nationwide Cohort Study. Diabetes Technology & Therapeutics 2019, 21: 702-712. PMID: 31418588, PMCID: PMC7207017, DOI: 10.1089/dia.2019.0213.Peer-Reviewed Original ResearchConceptsSodium-glucose cotransporter 2 inhibitorsGlucose-lowering medicationsHeart failureKidney diseaseMyocardial infarctionHigh-quality diabetes careMedicare Advantage insurancePrevalent adverse effectsRenal protective benefitsTreatment-risk paradoxNationwide cohort studyCotransporter 2 inhibitorsGlucose-lowering therapyPrior myocardial infarctionGlucose lowering medicationsChronic diabetes complicationsMultivariable logistic regressionNon-black patientsType 2 diabetesDiabetes type 1Insurance-related factorsCommercial health insuranceAppropriateness of usePrior hypoglycemiaSGLT2i initiation